SV

Savara IncNASDAQ SVRA Stock Report

Last reporting period 31 Dec, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0.728

Micro

Exchange

XNAS - Nasdaq

SVRA Stock Analysis

SV

Uncovered

Savara Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.728

Dividend yield

Shares outstanding

114.04 B

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), a inhaled biologic, is a granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

View Section: Eyestock Rating